Related Experiment Video
Updated: Aug 14, 2025
09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.5K
HiJAKing Immunotherapy-Resistant Melanoma for a Cure
Lewis Zhichang Shi1,2,3,4,5, Hongxing Shen1, Oluwagbemiga A Ojo1
1Department of Radiation Oncology, Heersink School of Medicine at the University of Alabama at Birmingham (UAB-SOM), Birmingham, AL, USA.
The Oncologist
|January 14, 2023
Summary
Immune checkpoint blockers (ICBs) show promise for advanced melanoma, but resistance limits their effectiveness. This commentary reviews recent research on overcoming ICB resistance in melanoma patients.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Advanced melanoma was historically difficult to treat.
- Immune checkpoint blockers (ICBs) have improved outcomes for some melanoma patients.
- Therapeutic resistance to ICBs remains a significant clinical challenge.
Purpose of the Study:
- To provide a commentary on recent research regarding immune checkpoint blocker resistance in melanoma.
- To highlight key findings and future directions in understanding and overcoming resistance.
Main Methods:
- Review of recent scientific literature and clinical studies on ICB resistance in melanoma.
- Analysis of emerging therapeutic strategies and biomarkers.
Main Results:
- Multiple mechanisms contribute to ICB resistance in melanoma.
- Emerging research focuses on combination therapies and novel drug targets.
- Biomarkers for predicting response and resistance are under investigation.
Conclusions:
- Understanding ICB resistance is crucial for improving melanoma treatment efficacy.
- Further research is needed to develop effective strategies to overcome resistance.
- Personalized treatment approaches may enhance outcomes for melanoma patients receiving ICBs.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
621
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
621
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:50Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K